Compare Stocks: CTEV, SDGR, CERT, and GDRX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CERT Certara	$7.63 -1.4%	$7.71	$4.45 ▼ $13.88	$1.18B	1.4	2.25 million shs	1.46 million shs
CTEV Claritev	$36.51 -3.2%	$32.22	$11.50 ▼ $73.68	$639.09M	0.88	118,863 shs	119,202 shs
GDRX GoodRx	$3.34 -5.1%	$3.32	$1.77 ▼ $5.81	$1.21B	1.59	1.52 million shs	1.29 million shs
SDGR Schrodinger	$19.20 -4.1%	$17.54	$10.94 ▼ $23.02	$1.48B	1.69	968,479 shs	755,926 shs

10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CERT Certara	-1.42%	-7.85%	-5.45%	+44.78%	-30.38%
CTEV Claritev	-2.69%	-8.68%	+8.86%	+13.46%	-49.40%
GDRX GoodRx	-5.11%	-3.19%	-8.74%	+27.00%	-19.13%
SDGR Schrodinger	-4.14%	-8.05%	+2.29%	+31.51%	-1.34%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CERT Certara	$7.63 -1.4%	$7.71	$4.45 ▼ $13.88	$1.18B	1.4	2.25 million shs	1.46 million shs
CTEV Claritev	$36.51 -3.2%	$32.22	$11.50 ▼ $73.68	$639.09M	0.88	118,863 shs	119,202 shs
GDRX GoodRx	$3.34 -5.1%	$3.32	$1.77 ▼ $5.81	$1.21B	1.59	1.52 million shs	1.29 million shs
SDGR Schrodinger	$19.20 -4.1%	$17.54	$10.94 ▼ $23.02	$1.48B	1.69	968,479 shs	755,926 shs

10 Stocks Powering The Next AI Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CERT Certara	-1.42%	-7.85%	-5.45%	+44.78%	-30.38%
CTEV Claritev	-2.69%	-8.68%	+8.86%	+13.46%	-49.40%
GDRX GoodRx	-5.11%	-3.19%	-8.74%	+27.00%	-19.13%
SDGR Schrodinger	-4.14%	-8.05%	+2.29%	+31.51%	-1.34%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CERT Certara	2.45	Hold	$8.28	8.49% Upside
CTEV Claritev	2.56	Moderate Buy	$44.83	22.80% Upside
GDRX GoodRx	2.08	Hold	$4.23	26.57% Upside
SDGR Schrodinger	2.29	Hold	$20.50	6.77% Upside

Current Analyst Ratings Breakdown

Latest CTEV, SDGR, CERT, and GDRX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/27/2026	SDGR Schrodinger	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/20/2026	GDRX GoodRx	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Underweight	$3.00 ➝ $4.00
8/20/2026	CTEV Claritev	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$28.00 ➝ $40.00
8/14/2026	SDGR Schrodinger	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Neutral	$13.00 ➝ $19.00
8/14/2026	SDGR Schrodinger	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Neutral	$13.00 ➝ $19.00
8/13/2026	GDRX GoodRx	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$2.50 ➝ $3.75
8/13/2026	CTEV Claritev	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/12/2026	SDGR Schrodinger	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/12/2026	CTEV Claritev	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$73.00
8/12/2026	CTEV Claritev	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Equal Weight	$22.00 ➝ $30.00
8/11/2026	GDRX GoodRx	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$4.00 ➝ $5.00

(Data available from 9/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CERT Certara	$418.84M	2.78	$0.75 per share	10.23	$6.67 per share	1.14
CTEV Claritev	$965.41M	0.64	$14.96 per share	2.44	($10.10) per share	-3.61
GDRX GoodRx	$796.85M	1.44	$0.38 per share	8.80	$1.81 per share	1.85
SDGR Schrodinger	$255.87M	5.54	N/A	N/A	$4.94 per share	3.89

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CERT Certara	-$1.60M	-$0.45	N/A	27.25	N/A	-16.75%	3.86%	2.65%	11/5/2026 (Estimated)
CTEV Claritev	-$284.28M	-$17.01	N/A	N/A	N/A	-28.46%	N/A	-5.76%	N/A
GDRX GoodRx	$30.44M	$0.04	83.52	16.70	1.75	2.07%	7.22%	2.53%	11/3/2026 (Estimated)
SDGR Schrodinger	-$103.26M	-$0.74	N/A	N/A	N/A	-20.98%	-16.37%	-8.19%	11/4/2026 (Estimated)

Latest CTEV, SDGR, CERT, and GDRX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2026	Q2 2026	CTEV Claritev	-$4.10	$1.41	+$5.51	-$3.49	N/A	$257.48 million
8/5/2026	Q2 2026	GDRX GoodRx	$0.0797	$0.08	+$0.0003	$0.02	$193.23 million	$200.41 million
8/5/2026	Q2 2026	SDGR Schrodinger	-$0.4145	$0.08	+$0.4945	$0.08	$47.19 million	$58.89 million
8/4/2026	Q2 2026	CERT Certara	$0.0893	$0.08	-$0.0093	-$0.36	$98.09 million	$93.27 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CERT Certara	N/A	N/A	N/A	N/A	N/A
CTEV Claritev	N/A	N/A	N/A	N/A	N/A
GDRX GoodRx	N/A	N/A	N/A	N/A	N/A
SDGR Schrodinger	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CERT Certara	0.30	2.55	2.55
CTEV Claritev	N/A	1.00	1.00
GDRX GoodRx	0.74	1.38	1.38
SDGR Schrodinger	N/A	2.71	2.71

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CERT Certara	73.96%
CTEV Claritev	87.15%
GDRX GoodRx	63.77%
SDGR Schrodinger	79.05%

Insider Ownership

Company	Insider Ownership
CERT Certara	1.08%
CTEV Claritev	7.40%
GDRX GoodRx	5.87%
SDGR Schrodinger	10.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CERT Certara	1,576	152.54 million	150.89 million	Optionable
CTEV Claritev	3,000	16.95 million	15.69 million	Optionable
GDRX GoodRx	950	342.57 million	322.47 million	Optionable
SDGR Schrodinger	790	73.82 million	66.37 million	Optionable

CTEV, SDGR, CERT, and GDRX Headlines

Recent News About These Companies

Schrodinger Establishes Tectora Therapeutics With RA Capital, New Enterprise Associates

2 hours ago | finance.yahoo.com

Tectora Therapeutics inc. announced that it has received $55 million in funding from New Enterprise Associates, Inc., RA Capital Management, L.P., Schrödinger, Inc.

September 9 at 5:46 PM | marketscreener.comM

Schrödinger Announces Licensing and Collaboration Agreement with Tectora Therapeutics, a New Biotechnology Company It Co-founded to Advance Immunology and Inflammation Programs

September 9 at 7:26 AM | finance.yahoo.com

Legal & General Group Plc Invests $2.29 Million in Schrodinger, Inc. $SDGR

September 6, 2026 | marketbeat.com

Bank of New York Mellon Corp Makes New Investment in Schrodinger, Inc. $SDGR

September 5, 2026 | marketbeat.com

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 438,798 Shares of Schrodinger, Inc. $SDGR

September 4, 2026 | marketbeat.com

Schrodinger (NASDAQ:SDGR) Shares Down 4.5% - Here's Why

September 2, 2026 | marketbeat.com

Schrodinger (NASDAQ:SDGR) Trading 4.6% Higher - Should You Buy?

September 1, 2026 | marketbeat.com

Schrödinger to Present at Morgan Stanley Global Healthcare Conference

September 1, 2026 | businesswire.com

Beacon Pointe Advisors LLC Takes Position in Schrodinger, Inc. $SDGR

September 1, 2026 | marketbeat.com

Deutsche Bank AG Purchases Shares of 62,368 Schrodinger, Inc. $SDGR

August 31, 2026 | marketbeat.com

Connor Clark & Lunn Investment Management Ltd. Makes New $3.18 Million Investment in Schrodinger, Inc. $SDGR

August 29, 2026 | marketbeat.com

BlackRock Inc. Buys New Shares in Schrodinger, Inc. $SDGR

August 29, 2026 | marketbeat.com

Algert Global LLC Trims Stake in Schrodinger, Inc. $SDGR

August 28, 2026 | marketbeat.com

71,397 Shares in Schrodinger, Inc. $SDGR Bought by Ieq Capital LLC

August 27, 2026 | marketbeat.com

Schrödinger, Inc. (SDGR) Stock Price, News, Quote & History - Yahoo Finance

August 25, 2026 | finance.yahoo.com

Schrodinger, Inc. (NASDAQ:SDGR) Receives Average Recommendation of "Hold" from Analysts

August 25, 2026 | marketbeat.com

Schrödinger: The Software Business Is Stronger Than It Looks

August 22, 2026 | seekingalpha.com

Tejara Capital Ltd Takes $4.55 Million Position in Schrodinger, Inc. $SDGR

August 21, 2026 | marketbeat.com

Schrodinger (NASDAQ:SDGR) Trading 10.4% Higher - What's Next?

August 19, 2026 | marketbeat.com

4 AI-Powered Drug Discovery Stocks to Watch as AI Reshapes Pharma

August 17, 2026 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

CTEV, SDGR, CERT, and GDRX Company Descriptions

Certara NASDAQ:CERT

$7.63 -0.11 (-1.42%)

Closing price 09/9/2026 04:00 PM Eastern

Extended Trading

$7.62 -0.01 (-0.20%)

As of 04:03 AM Eastern

Certara, Inc., together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics. The company provides Simcyp Simulator, a mechanistic biosimulation platform mechanistic biosimulation investigational new drug and translational stages; Simcyp Biopharmaceutics, used to identify and refine drug formulations; and Simcyp Secondary Intelligence which integrates toxicology with quantitative analysis of networks of molecular and functional biological changes to identify drug toxicity and adverse drug reactions. In addition, it offers Phoenix WinNonlin, a platform for non-compartmental analysis, pharmacokinetic/pharmacodynamic, and toxicokinetic; phoenix hosted, that provides a secured and validated certara amazon web services workspace; Phoenix NLME, a population modeling and simulation software for nonlinear mixed effects models; and pirana modeling workbench. Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange, used to define data standards and specifications; and Metadata Repository, to enable study design using controlled and standardized data. It serves life sciences companies, biopharmaceutical companies, research organizations, academic institutions, and global regulators, as well as animal health, crop science, bio science, medical devices, and public sector industries. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.

Claritev NYSE:CTEV

$36.51 -1.20 (-3.18%)

As of 09/9/2026 03:58 PM Eastern

MultiPlan Corporation, together with its subsidiaries, provides data analytics and technology-enabled cost management, payment, and revenue integrity solutions to the healthcare industry in the United States. The company offers analytics-based services that reduce medical costs, through data-driven algorithms and insights that detect claims over-charges and negotiate or recommend reimbursement; and network-based services that provide contracted discounts with healthcare providers, as well as outsourced network development and management services. It provides payment and revenue integrity services, such as identifying and removing improper and unnecessary charges paid during the claim, as well as services to identify and help restore and preserve underpaid premium dollars. In addition, the company offers data and decision science services including a suite of solutions that apply modern methods of data science to produce descriptive, predictive, and prescriptive analytics that drive optimized benefit plan design, support decision-making, improve clinical outcomes, and reduce the total cost of care; and business-to-business healthcare payments and other services. It serves national and regional insurance companies, Blue Cross and Blue Shield plans, provider-sponsored and independent health plans, TPAs, self-insured health plans, property and casualty insurers, bill review companies, and other companies involved in the claim adjudication process. MultiPlan Corporation was founded in 1980 and is headquartered in New York, New York.

GoodRx NASDAQ:GDRX

$3.34 -0.18 (-5.11%)

Closing price 09/9/2026 04:00 PM Eastern

Extended Trading

$3.35 +0.01 (+0.30%)

As of 05:04 AM Eastern

GoodRx Holdings, Inc., together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices. It also offers other healthcare products and services, including subscriptions, and pharma manufacturer solutions, as well as telehealth services through the GoodRx Care platform. It serves pharmacy benefit managers who manage formularies and prescription transactions, including establishing pricing between consumers and pharmacies. The company was founded in 2011 and is headquartered in Santa Monica, California.

Schrodinger NASDAQ:SDGR

$19.20 -0.83 (-4.14%)

Closing price 09/9/2026 04:00 PM Eastern

Extended Trading

$19.20 0.00 (-0.03%)

As of 05:29 AM Eastern

Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CTEV, SDGR, CERT, and GDRX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CTEV, SDGR, CERT, and GDRX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CTEV, SDGR, CERT, and GDRX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

CTEV, SDGR, CERT, and GDRX Company Descriptions

Certara NASDAQ:CERT

Claritev NYSE:CTEV

GoodRx NASDAQ:GDRX

Schrodinger NASDAQ:SDGR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CTEV, SDGR, CERT, and GDRX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CTEV, SDGR, CERT, and GDRX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CTEV, SDGR, CERT, and GDRX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

CTEV, SDGR, CERT, and GDRX Company Descriptions

Certara NASDAQ:CERT

Claritev NYSE:CTEV

GoodRx NASDAQ:GDRX

Schrodinger NASDAQ:SDGR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools